Mast Therapeutics Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
January 7, 2016 12:01 PM ESTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $5 price target on Mast Therapeutics (NYSE: MSTX) noting pivotal data in sickle cell ahead and pipeline progress.
Kolbert highlighted:
Management provided a detailed update, highlighting key clinical and regulatory milestones in 2016 including the status of the pivotal phase III "EPIC" study (N=388) of vepoloxamer in sickle cell disease (SCD). We remain... More